Image pharmaphorum Editor Digital Targeted agents and immunotherapies Targeted agents and immunotherapies are two of the most promising areas for significant advancements in cancer treatment. Patients Putting patient perspectives at the heart of kidney cancer r... Commissioned by Ipsen. Digital An open call for innovation There is a bright future ahead for open innovation in pharma, as Almirall executive vice-president, research and development chief scientific officer Karl Ziegelbauer explains. Digital Understanding the prevention and treatment needs for cardiov... What does the current picture of cardiovascular disease in Europe look like? Load more results
Digital Targeted agents and immunotherapies Targeted agents and immunotherapies are two of the most promising areas for significant advancements in cancer treatment.
Digital An open call for innovation There is a bright future ahead for open innovation in pharma, as Almirall executive vice-president, research and development chief scientific officer Karl Ziegelbauer explains.
Digital Understanding the prevention and treatment needs for cardiov... What does the current picture of cardiovascular disease in Europe look like?
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
